Hybrid PET/CT enhanced with intravenous CT contrast deserves wider acceptance and adoption, as diagnostically optimized CT can complement PET—and vice versa—for a variety of potential indications. That’s one opinion on the matter.

Randall Thompson, MD, immediate past president of the American Society of Nuclear Cardiology (ASNC), explains two key advances in cardiac nuclear imaging.
 

Brain MRI of the choroid plexus, the main supplier of cerebrospinal fluid, can deliver independent biomarkers for Alzheimer’s disease without an assist from clinical tests for amyloid abnormality or neurodegeneration. 

In pediatric care settings, hybrid PET/MR imaging combines “exquisite soft-tissue information obtained by MR imaging with functional information provided by PET.”

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

Randall Thompson, MD, immediate past president of the American Society of Nuclear Cardiology (ASNC), explains the current ASNC lobbying efforts.

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

Over the past few weeks, members of ASNC’s Health Policy Committee have held meetings with their members of Congress.